Vevye + Flarex Combination Therapy for Dry Eye

Part of paid clinical trials in Azusa, California.

Sponsor
Canyon City Eyecare
Study ID
NCT07553455
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vevye(Cyclosporine 0.1% Ophthalmic Solution) — DRUG
    Vevye (cyclosporine ophthalmic solution) is administered twice daily (BID) in both eyes for the treatment of dry eye disease.
  • Flarex — DRUG
    Flarex (fluorometholone acetate ophthalmic suspension) is administered four times daily (QID) in both eyes. Doses are separated from Vevye by approximately 10 minutes.

Study Details

This study evaluates the safety and efficacy of combination therapy with Vevye (cyclosporine ophthalmic solution) and Flarex (fluorometholone acetate ophthalmic suspension) in adults with moderate to severe dry eye disease. Participants receive Vevye twice daily and Flarex four times daily, with outcomes assessed over a 1-month period.

Key Dates

Start date
Apr 3, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination Therapy Arm
    Participants receive Vevye (cyclosporine ophthalmic solution) twice daily and Flarex (fluorometholone acetate ophthalmic suspension) four times daily.

Primary Outcome Measure

VAS [ Time Frame: Baseline to 1 Month ]

Locations (1)

FacilityCityStateZIPSite coordinators
Canyon City EyecareAzusaCalifornia91702-

Find similar trials in Azusa, CA

By research site
Canyon City Eyecare· Azusa, CA

Related Studies